Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic dendritic cell-autologous tumor cell fusion vaccine
- Development stage
- Unknown
- Lead developer
- Beth Israel Deaconess Medical Center
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Subcutaneous
01
Overview
The allogeneic dendritic cell-autologous tumor cell fusion vaccine is an investigational cancer immunotherapy developed by researchers at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute. This biologic vaccine is created by fusing healthy donor-derived (allogeneic) dendritic cells with a patient's own (autologous) tumor cells using electrical pulses, a process known as electrofusion. The resulting hybrid cells combine the potent antigen-presenting and costimulatory capabilities of dendritic cells with the broad array of tumor-associated antigens found in the patient's cancer. This approach is designed to activate the patient's immune system, specifically inducing a tumor-specific cytotoxic T lymphocyte response to target and eliminate metastatic renal cell carcinoma cells.
- Other names
- Electrofusion DC vaccineDC-tumor cell fusion vaccineAllogeneic DC-autologous tumor cell fusion vaccine
Beyond the preview
Go deeper on Allogeneic dendritic cell-autologous tumor cell fusion vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic dendritic cell-autologous tumor cell fusion vaccine.